Is there a place for granulocyte colony-stimulating factor in non-neutropenic critically ill patients?

Intensive Care Medicine

Volumn 30, Issue 1, 2004, Pages 10-17

  Azoulay, Élle ^a   Delclaux, Christophe ^b  

^a SAINT LOUIS HOSPITAL   (France)

^b HENRI MONDOR HOSPITAL   (France)

Author keywords

Acute respiratory distress syndrome; Controlled trials; Experimental; Granulocyte colony stimulating factor (G CSF); Immunomodulation; Intensive care; Neutrophils; Randomised controlled trials; Safety; Sepsis

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR;

ACUTE RESPIRATORY TRACT DISEASE; BACTERIAL MENINGITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CRITICAL ILLNESS; DIABETIC FOOT; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOPHARMACOLOGY; IMMUNOTHERAPY; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; LIVER FAILURE; LIVER TRANSPLANTATION; MACROPHAGE; MONOCYTE; MULTICENTER STUDY; NEUTROPHIL; NEWBORN SEPSIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR UPREGULATION; RESPIRATORY DISTRESS SYNDROME; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT INDICATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CRITICAL CARE; CRITICAL ILLNESS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INFECTION; MACROPHAGES; MONOCYTES; NEUTROPENIA; NEUTROPHILS; PATIENT SELECTION; PNEUMONIA; SAFETY; TREATMENT OUTCOME;

EID: 0742304355     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-003-2049-8     Document Type: Review

References (75)

1. Lieschke GJ, Burgess AW (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). N Engl J Med 327:99-106
2. Andres E, Kurtz JE, Perrin AE, Dufour P, Schlieriger JL, Maloisel F (2001) Haematopoietic growth factor in anti-thyroid-drug-induced agranulocytosis. QJM 94:423-428
3. Boogaerts M, Cavalli F, Cortes-Funes H, Gatell JM, Gianni AM, Khayat D, Levy Y, Link H (1995) Granulocyte growth factors: achieving a consensus. Ann Oncol 6:237-244
4. Weite K, Gabrilove J, Bronchud MH, Platzer E, Morstyn G (1996) Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88:1907-1929
5. Bishop MR, Tarantolo SR, Geller RB, Lynch JC, Bierman PJ, Pavletic ZS, Vose JM, Kruse S, Dix SP, Morris ME, Armitage JO, Kessinger A (2000) A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 96:80-85
6. Schmaldienst S, Bekesi G, Deicher R, Franz M, Horl WH, Pohanka E (2000) Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation 69:527-531
7. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18:395-404
8. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384-1391
9. Dale DC, Liles WC, Summer WR, Nelson S (1995) Review: granulocyte colony-stimulating factor - role and relationships in infectious diseases. J Infect Dis 172:1061-1075
10. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A (1992) Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80:2012-2020
11. Basu S, Dunn A, Ward A (2002) G-CSF: function and modes of action (Review). Int J Mol Med 10:3-10
12. Hollenstein U, Homoncik M, Stohlawetz PJ, Marsik C, Sieder A, Eichler HG, Jilma B (2000) Endotoxin down-modulates granulocyte colony-stimulating factor receptor (CD114) on human neutrophils. J Infect Dis 182:343-346
13. Weiss M, Moldawer LL, Schneider EM (1999) Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 93:425-439
14. Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T (2000) Human monocytes express functional receptors for granulocyte colony-stimulating factor that mediate suppression of monokines and interferon-gamma. Blood 95:270-276
15. Tanaka H, Nishino M, Nakamori Y, Ogura H, Ishikawa K, Shimazu T, Sugimoto H (2001) Granulocyte colony-stimulating factor (G-CSF) stiffens leukocytes but attenuates inflammatory response without lung injury in septic patients. J Trauma 51:1110-1116
16. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD, Kox W (1997) Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat Med 3:678-681
17. Stephan F, Yang K, Tankovic J, Soussy CJ, Dhonneur G, Duvaldestin P, Brochard L, Brun-Buisson C, Harf A, Delclaux C (2002) Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 30:315-322
18. Solberg CO, Helium KB (1972) Neutrophil granulocyte function in bacterial infections. Lancet 2:727-730
19. Christou NV, Meakins JL (1979) Neutrophil function in anergic surgical patients: neutrophil adherence and chemotaxis. Ann Surg 190:557-564
20. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM (1991) Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 88:1747-1754
21. Jacobs RF, Kiel DP, Balk RA (1986) Alveolar macrophage function in a canine model of endotoxin-induced lung injury. Am Rev Respir Dis 134:745-751
22. Weiss M, Gross-Weege W, Schneider M, Neidhardt H, Liebert S, Mirow N, Wemet P (1995) Enhancement of neutrophil function by in vivo filgrastim treatment for prophylaxis of sepsis in surgical intensive care patients. J Crit Care 10:21-26
23. Weiss M, Gross-Weege W, Harms B, Schneider EM (1996) Filgrastim (RHG-CSF) related modulation of the inflammatory response in patients at risk of sepsis or with sepsis. Cytokine 8:260-265
24. Gross-Weege W, Weiss M, Schneider M, Wenning M, Harms B, Dumon K, Ohmann C, Roher HD (1997) Safety of a low-dosage Filgrastim (rhG-CSF) treatment in non-neutropenic surgical intensive care patients with an inflammatory process. Intensive Care Med 23:16-22
25. Gerber A, Struy H, Weiss G, Lippert H, Ansorge S, Schulz HU (2000) Effect of granulocyte colony-stimulating factor treatment on ex vivo neutrophil functions in nonneutropenic surgical intensive care patients. J Interferon Cytokine Res 20:1083-1090
26. Weiss M, Voglic S, Harms-Schirra B, Lorenz I, Lasch B, Dumon K, Gross-Weege W, Schneider EM (2003) Effects of exogenous recombinant human granulocyte colony-stimulating factor (filgrastim, rhG-CSF) on neutrophils of critically ill patients with systemic inflammatory response syndrome depend on endogenous G-CSF plasma concentrations on admission. Intensive Care Med 29:904-914
27. Yang K, Azoulay E, Attalah L, Zahar JR, Van de Louw A, Cerf C, Soussy CJ, Duvaldestin P, Brochard L, Brun-Buisson C, Harf A, Delclaux C (2003) Bactericidal activity response of blood neutrophils from critically ill patients to in vitro granulocyte colony-stimulating factor stimulation. Intensive Care Med 29:396-402
28. Nelson S, Belknap SM, Carlson RW, Dale D, DeBoisblanc B, Farkas S, Fotheringham N, Ho H, Marrie T, Movahhed H, Root R, Wilson J (1998) A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. CAP Study Group. J Infect Dis 178:1075-1080
29. Fiuza C, Salcedo M, Clemente G, Tellado JM (2002) Granulocyte colony-stimulating factor improves deficient in vitro neutrophil transendothelial migration in patients with advanced liver disease. Clin Diagn Lab Immunol 9:433-439
30. Noursadeghi M, Bickerstaff MC, Herbert J, Moyes D, Cohen J, Pepys MB (2002) Production of granulocyte colony-stimulating factor in the non-specific acute phase response enhances host resistance to bacterial infection. J Immunol 169:913-919
31. Zhang P, Bagby GJ, Stoltz DA, Summer WR, Nelson S (1999) Granulocyte colony-stimulating factor modulates the pulmonary host response to endotoxin in the absence and presence of acute ethanol intoxication. J Infect Dis 179:1441-1448
32. Freeman BD, Quezado Z, Zeni F, Natanson C, Danner RL, Banks S, Quezado M, Fitz Y, Bacher J, Eichacker PQ (1997) rG-CSF reduces endotoxemia and improves survival during E. coli pneumonia. J Appl Physiol 83:1467-1475
33. Smith WS, Sumnicht GE, Sharpe RW, Samuelson D, Millard FE (1995) Granulocyte colony-stimulating factor versus placebo in addition to penicillin G in a randomized blinded study of gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 86:1301-1309
34. Shirai R, Kadota J, Tomono K, Ogawa K, Iida K, Kawakami K, Kohno S (1997) Protective effect of granulocyte colony-stimulating factor (G-CSF) in a granulocytopenic mouse model of Pseudomonas aeruginosa lung infection through enhanced phagocytosis and killing by alveolar macrophages through priming tumour necrosis factor-alpha (TNF-alpha) production. Clin Exp Immunol 109:73-79
35. Nelson S, Summer W, Bagby G, Nakamura C, Stewart L, Lipscomb G, Andresen J (1991) Granulocyte colony-stimulating factor enhances pulmonary host defenses in normal and ethanol-treated rats. J Infect Dis 164:901-906
36. Hebert JC, O'Reilly M, Gamelli RL (1990) Protective effect of recombinant human granulocyte colony-stimulating factor against pneumococcal infections in splenectomized mice. Arch Surg 125:1075-1078
37. Dallaire F, Ouellet N, Simard M, Bergeron Y, Bergeron MG (2001) Efficacy of recombinant human granulocyte colony-stimulating factor in a murine model of pneumococcal pneumonia: effects of lung inflammation and timing of treatment. J Infect Dis 183:70-77
38. Chiller T, Farrokhshad K, Brummer E, Stevens DA (2002) Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorpho-nuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans. Med Mycol 40:21-26
39. Patton JH Jr, Lyden SP, Ragsdale DN, Croce MA, Fabian TC, Proctor KG (1998) Granulocyte colony-stimulating factor improves host defense to resuscitated shock and polymicrobial sepsis without provoking generalized neutrophil-mediated damage. J Trauma 44:750-758; discussion 758-759
40. Abraham E, Stevens P (1992) Effects of granulocyte colony-stimulating factor in modifying mortality from Pseudomonas aeruginosa pneumonia after hemorrhage. Crit Care Med 20:1127-1133
41. Attalah HL, Azoulay E, Yang K, Lasclos C, Jouault H, Soussy CJ, Guillot T, Brochard L, Brun-Buisson C, Harf A, Delclaux C (2002) Granulocyte colony-stimulating factor enhances host defenses against bacterial pneumonia following peritonitis in nonneutropenic rats. Crit Care Med 30:2107-2114
42. Quezado Z, Parent C, Karzai W, Depietro M, Natanson C, Hammond W, Danner RL, Cui X, Fitz Y, Banks SM, Gerstenberger E, Eichacker PQ (2001) Acute G-CSF therapy is not protective during lethal E. coli sepsis. Am J Physiol Regul Integr Comp Physiol 281:R1177-1185
43. DeBoisblanc BP, Mason CM, Andresen J, Logan E, Bear MB, Johnson S, Shellito J, Summer WR, Nelson S (1997) Phase 1 safety trial of Filgrastim (r-metHuG-CSF) in non-neutropenic patients with severe community-acquired pneumonia. Respir Med 91:387-394
44. Nelson S, Heyder AM, Stone J, Bergeron MG, Daugherty S, Peterson G, Fotheringham N, Welch W, Milwee S, Root R (2000) A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis 182:970-973
45. Nelson S (2001) Novel nonantibiotic therapies for pneumonia: cytokines and host defense. Chest 119:419S-425S
46. Heard SO, Fink MP, Gamelli RL, Solomkin JS, Joshi M, Trask AL, Fabian TC, Hudson LD, Gerald KB, Logan ED (1998) Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. Crit Care Med 26:748-754
47. Pettila V, Takkunen O, Varpula T, Markkola A, Porkka K, Valtonen V (2000) Safety of granulocyte colony-stimulating factor (filgrastim) in intubated patients in the intensive care unit: interim analysis of a prospective, placebo-controlled, double-blind study. Crit Care Med 28:3620-3625
48. Wunderink R, Leeper K Jr, Schein R, Nelson S, DeBoisblanc B, Fotheringham N, Logan E (2001) Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 119:523-529
49. Meyanci G, Oz H (2001) Combination of granulocyte colony-stimulating factor and antibacterial drugs for the treatment of ventilatory associated nosocomial pneumonia. Middle East J Anesthesiol 16:91-101
50. Stephens DP, Fisher DA, Currie BJ (2002) An audit of the use of granulocyte colony-stimulating factor in septic shock. Intern Med J 32:143-148
51. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S (2003) Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalized with pneumonia and severe sepsis. Crit Care Med 31:367-373
52. Tate RM, Repine JE (1983) Neutrophils and the adult respiratory distress syndrome. Am Rev Respir Dis 128:552-559
53. Weiss SJ (1989) Tissue destruction by neutrophils. N Engl J Med 320:365-376
54. Freeman BD, Correa R, Karzai W, Natanson C, Patterson M, Banks S, Fitz Y, Danner RL, Wilson L, Eichacker PQ (1996) Controlled trials of rG-CSF and CD11b-directed MAb during hyperoxia and E. coli pneumonia in rats. J Appl Physiol 80:2066-2076
55. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, Banks SM, Eichacker PQ (1999) G-CSF during Escherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 159:1377-1382
56. King J, Deboisblanc BP, Mason CM, Onofrio JM, Lipscomb G, Mercante DE, Summer WR, Nelson S (1995) Effect of granulocyte colony-stimulating factor on acute lung injury in the rat. Am J Respir Crit Care Med 151:302-309
57. Terashima T, Kanazawa M, Sayama K, Ishizaka A, Urano T, Sakamaki F, Nakamura H, Waki Y, Tasaka S (1994) Granulocyte colony-stimulating factor exacerbates acute lung injury induced by intratracheal endotoxin in guinea pigs. Am J Respir Crit Care Med 149:1295-1303
58. Azoulay E, Attalah H, Yang K, Jouault H, Schlemmer B, Brun-Buisson C, Brochard L, Harf A, Delclaux C (2002) Exacerbation by granulocyte colony-stimulating factor of prior acute lung injury: implication of neutrophils. Crit Care Med 30:2115-2122
59. Azoulay E, Attalah H, Yang K, Herigault S, Jouault H, Brun-Buisson C, Brochard L, Harf A, Schlemmer B, Delclaux C (2003) Exacerbation with granulocyte-colony stimulating factor of prior acute lung injury during neutropenia recovery in rats. Crit Care Med 31:157-165
60. Azoulay E, Attalah H, Harf A, Schlemmer B, Delclaux C (2001) Granulocyte colony-stimulating factor or neutrophil-induced pulmonary toxicity: myth or reality? Systematic review of clinical case reports and experimental data. Chest 120:1695-1701
61. Armstrong WS, Kazanjian P (2001) Use of cytokines in human immunodeficiency virus-infected patients: colony-stimulating factors, erythropoietin and interleukin-2. Clin Infect Dis 32:766-773
62. Dubreuil-Lemaire ML, Gori A, Vittecoq D, Panelatti G, Tharaux F, Palisses R, Gharakhanian S, Rozenbaum W (2000) Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalo-virus infection: a randomised, placebo-controlled trial in AIDS patients. Eur J Haematol 65:337-343
63. Reiser P, Rademacher S, Smith JW, Skiest D, Vadde V (1998) Granulocyte colony-stimulating factor use is associated with decreased bacteremia and increased survival in neutropenic HIV-infected patients. Am J Med 104:48-55
64. Kuritzkes DR (2000) Neutropenia, neutrophil dysfunction and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 30:256-260
65. Gessler P, Kirchmann N, Kientsch-Engel R, Haas N, Lasch P, Kachel W (1993) Serum concentrations of granulocyte colony-stimulating factor in healthy term and preterm neonates and in those with various diseases including bacterial infections. Blood 82:3177-3182
66. Miura E, Procianoy RS, Bittar C, Miura CS, Miura MS, Mello C, Christensen RD (2001) A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics 107:30-35
67. De Lalla F, Nicolin R, Lazzarini L (2000) Safety and efficacy of recombinant granulocyte colony-stimulating factor as an adjunctive therapy for Streptococcus pneumoniae meningitis in non-neutropenic adult patients: a pilot study. J Antimicrob Chemother 46:843-846
68. Chantelau E, Kimmerle R (1998) Granulocyte-colony-stimulating factor in diabetic foot infection. Lancet 351:370
69. De Lalla F, Pellizzer G, Strazzabosco M, Martini Z, Du Jardin G, Lora L, Fabris P, Benedetti P, Erle G (2001) Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection. Antimicrob Agents Chemother 45:1094-1098
70. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME (1997) Randomised placebo-controlled trial of granulocytecolony stimulating factor in diabetic foot infection. Lancet 350:855-859
71. Yonem A, Cakir B, Guler S, Azal OO, Corakci A (2001) Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 3:332-337
72. Rolando N, Clapperton M, Wade J, Wendon J (2000) Administering granulocyte colony-stimulating factor to acute liver failure patients corrects neutrophil defects. Eur J Gastroenterol Hepatol 12:1323-1328
73. Rolando N, Clapperton M, Wade J, Panetsos G, Mufti G, Williams R (2000) Granulocyte colony-stimulating factor improves function of neutrophils from patients with acute liver failure. Eur J Gastroenterol Hepatol 12:1135-1140
74. Foster PF, Mital D, Sankary HN, McChesney LP, Marcon J, Koukoulis G, Kociss K, Leurgans S, Whiting JF, Williams JW (1995) The use of granulocyte colony-stimulating factor after liver transplantation. Transplantation 59:1557-1563
75. Winston DJ, Foster PF, Somberg KA, Busuttil RW, Levy MF, Sheiner PA, Reddy KR, Fotheringham N, Armstrong M, Logan E (1999) Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation 68:1298-1304